Journal of the National Cancer Institute Advance Access originally published online on April 29, 2008
JNCI Journal of the National Cancer Institute 2008 100(9):610-613; doi:10.1093/jnci/djn127
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© The Author 2008. Published by Oxford University Press.
EDITORIALS |
A Model Citizen? Is Tamoxifen More Effective Than Aromatase Inhibitors if We Pick the Right Patients?
on behalf of the Consortium on Breast Cancer Pharmacogenomics
Affiliations of authors: The Breast Oncology Program, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI (DFH, JR); Breast Cancer Program, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, Baltimore, MD (VS); Division of Clinical Pharmacology, Department of Medicine, Indiana University School of Medicine, Indianapolis, IN (DF)
Correspondence to: Daniel F. Hayes, MD, The Breast Oncology Program, University of Michigan Comprehensive Cancer Center, 6312 Cancer Center, 1500 East Medical Center Drive, Ann Arbor, MI (e-mail: hayesdf@umich.edu).
| The first 150 words of the full text of this article appear below. |
After decades of empiricism, the treatment of cancer is widely felt to be entering the era of "targeted" therapy and leading to personalized strategies for individuals with this dreaded disease. Of course, the approach to targeted therapy in oncology is not a new one. Students of breast cancer history point to Sir George Beatson's report in 1896 of the clinical improvement he observed in three young women with locally advanced breast cancer following surgical oophorectomy (1). Subsequent landmark studies by Jensen, Lippman, and McGuire, among others, demonstrated that what Beatson had actually done was remove a specific growth factor, 17β-estradiol, from its cellular target, the estrogen receptor (ER) (2–4). Clinicians now routinely use tissue ER content to individualize antiestrogen therapy for breast cancer patients (5).
This example of personalized medicine is now joined by many others (6,7). Until
Funding
Related Articles in JNCI
CiteULike 
Connotea 
Del.icio.us What's this?
J Natl Cancer Inst 2008 100: 642-648.
J Natl Cancer Inst 2008 100: 603.
This article has been cited by other articles:
|
|
 |
|
  T. Toyama, H. Yamashita, H. Sugiura, N. Kondo, H. Iwase, and Y. Fujii No Association Between CYP2D6*10 Genotype and Survival of Node-negative Japanese Breast Cancer Patients Receiving Adjuvant Tamoxifen Treatment Jpn. J. Clin. Oncol., October 1, 2009; 39(10): 651 - 656. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Seruga and I. F. Tannock Up-Front Use of Aromatase Inhibitors As Adjuvant Therapy for Breast Cancer: The Emperor Has No Clothes J. Clin. Oncol., February 20, 2009; 27(6): 840 - 842. [Full Text] [PDF]
|
|
|
|
 |
|
 V. O. Dezentje, H.-J. Guchelaar, J. W.R. Nortier, C. J.H. van de Velde, and H. Gelderblom Clinical Implications of CYP2D6 Genotyping in Tamoxifen Treatment for Breast Cancer Clin. Cancer Res., January 1, 2009; 15(1): 15 - 21. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. L. Henry, V. Stearns, D. A. Flockhart, D. F. Hayes, and M. Riba Drug Interactions and Pharmacogenomics in the Treatment of Breast Cancer and Depression Am J Psychiatry, October 1, 2008; 165(10): 1251 - 1255. [Full Text] [PDF]
|
|
|
|
 |
|
 D. Gurwitz and W. Newman Re: Pharmacogenomic Variation of CYP2D6 and the Choice of Optimal Adjuvant Endocrine Therapy for Postmenopausal Breast Cancer: A Modeling Analysis J Natl Cancer Inst, September 17, 2008; 100(18): 1331 - 1331. [Full Text] [PDF]
|
|